Daré Bioscience, Inc. (NASDAQ:DARE) Q2 2021 Earnings Conference Call August 12, 2021 4:30 PM ET Company Participants Sabrina Martucci Johnson - President and CEO John Fair - CSO Lisa Walters-Hoffert - CFO Conference Call Participants Zegbeh Jallah - ROTH Capital Partners Doug Tsao - H. C. Wainwright Kumar Raja - Brookline Capital Markets Operator Thank you all for standing-by. And welcome to the conference call hosted by Daré Bioscience to review the Company’s Financial Results for the Quarter Ended June 30 ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to DARÉ BIOSCIENCE, INC. (Exact Name of Registrant as Specified in its Charter) Delaware (State or Other Jurisdiction of Incorporation) Commission File No. 001-3 ...

Daré Bioscience, Inc. (NASDAQ:DARE) Q1 2021 Earnings Conference Call May 13, 2021 4:30 PM ET Company Participants Sabrina Martucci Johnson – President and Chief Executive Officer John Fair – Chief Strategy Officer Lisa Walters-Hoffert – Chief Financial Officer Conference Call Participants Zegbeh Jallah – ROTH Capital Partners Chris Bialas – H.C. Wainwright Operator Welcome to the conference call hosted by Daré Bioscience to review the Company’s Financial Results for the Quarter Ended March 31, 2021, and to ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-36395 20-4139823 (IRS Employer Identification No.) 3655 Nobel Drive, Suite 260 San Diego, CA (Address of Principal Executive Offices) ...

Daré Bioscience, Inc. (NASDAQ:DARE) Q4 2020 Earnings Conference Call March 30, 2021 4:30 PM ET Corporate Participants Sabrina Martucci Johnson - President and Chief Executive Officer Lisa Walters-Hoffert - Chief Financial Officer John Fair - Chief Strategy Officer Conference Call Participants Zegbeh Jallah - ROTH Capital Partners Joanne Lee - Maxim Group Douglas Tsao - H.C. Wainwright Operator Welcome to the conference call hosted by Daré Bioscience to review the Company's Financial Results for the Year En ...

UNITED STATES For the fiscal year ended December 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM _____ TO_____ | --- | --- | |-------|-----------------------------------------------------------------------------------------------------------------| | | SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ___________________________________________________ | | | FORM 10-K _______________________________________________ ...

Daré Bioscience, Inc. (NASDAQ:DARE) Q3 2020 Results Earnings Conference Call November 12, 2020 4:30 PM ET Company Participants Sabrina Martucci Johnson - President and CEO John Fair - Chief Strategy Officer Lisa Walters-Hoffert - Chief Financial Officer Conference Call Participants Jason Kolbert - Dawson James Operator Welcome to the conference call hosted by Daré Bioscience to review the Company's Financial Results for the Quarter Ended September 30, 2020, and to provide a general business update. This cal ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to DARÉ BIOSCIENCE, INC. (Exact Name of Registrant as Specified in its Charter) Delaware (State or Other Jurisdiction of Incorporation) Commission File No. ...

Daré Bioscience, Inc. (NASDAQ:DARE) Q2 2020 Results Earnings Conference Call August 12, 2020 4:30 PM ET Company Participants Sabrina Martucci Johnson - President and CEO John Fair - Chief Strategy Officer Lisa Walters-Hoffert - Chief Financial Officer Conference Call Participants Nathan Weinstein - Aegis Capital Joanne Lee - the Maxim Group Operator Welcome to the conference call hosted by Daré Bioscience to review the Company's Financial Results for the Quarter Ended June 30, 2020, and to provide a general ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to DARÉ BIOSCIENCE, INC. (Exact Name of Registrant as Specified in its Charter) Delaware (State or Other Jurisdiction of Incorporation) Commission File No. 001-3 ...